Skip to main content
Back to News
Latent Labs Builds an AI Drug-Design Lab After Founder Simon Kohl’s DeepMind Exit
Technology
2 min read

Latent Labs Builds an AI Drug-Design Lab After Founder Simon Kohl’s DeepMind Exit

The AMW Read

Latent Labs is a new AI-bio player-map update, while Kohl’s move from DeepMind is a named top-lab talent transition without disclosed commercial milestones.
NoveltySignificance
Healthcare & Bio · Player MapTalent Dynamics
Latent Labs
Latent Labs

AI in Biotech / Drug Discovery

View Company Profile

Latent Labs Builds an AI Drug-Design Lab After Founder Simon Kohl’s DeepMind Exit

Simon Kohl, a DeepMind alumnus, left the company three years ago to found Latent Labs, an AI lab focused on drug design and discovery, according to a Sifted interview published September 24. Kohl characterized the move as a decision to pursue frontier work outside a large technology company. The available article text does not provide a financing figure, product launch, clinical program, or commercial partnership.

The development adds another founder-led entrant to the AI-bio field, where the central question is whether advances in model capability can translate into better drug-discovery economics and validated biological outcomes. A DeepMind research background can help a young company recruit technical talent and attract attention, but it does not itself establish a durable advantage in a market shaped by experimental validation, proprietary data, and lengthy development cycles. Kohl’s move is also a concrete example of senior research talent leaving a top AI lab to pursue a specialized commercial application.

For builders, the test is to connect model outputs to measurable laboratory and development decisions rather than treating protein design as a standalone model demonstration. For investors, Latent Labs should be evaluated against evidence of differentiated datasets, wet-lab feedback loops, scientific validation, and a credible path from designed proteins to drug-development value. Per the AI Market Watch index, the pipeline logged one name-matched Latent Labs item in the last 90 days versus none in the prior 90, limited to pipeline-ingested sources.

#AIBio #DrugDiscovery #ProteinDesign #DeepMind #LatentLabs

#Latent Labs#Simon Kohl#DeepMind#AI drug discovery#related:Founders Factory

How This Connects

Based on Healthcare & Bio · Player Map

  1. 4d agoIsomorphic Labs raises $5 billion Series C for AI drug discoveryIsomorphic Labs
  2. 0mo agoPathos AI raises $237M to scale Foundry and advance four oncology assetsPathos
  3. 1mo agoWarp Sciences raises $215 million for robotic drug-discovery labsWarp Sciences
  4. 1mo agoLatent Labs Builds an AI Drug-Design Lab After Founder Simon Kohl’s DeepMind Exit · THIS ARTICLE

More news from Latent Labs

Stay updated with the latest news and announcements from Latent Labs.

View all Latent Labs news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard